FOLH1 and prostate cancer: Eleven trials are about solid tumors (including ovarian cancer, prostate cancer, non-small cell lung cancer, pancreatic cancer, and glioblastoma), in which CAR-NK cells target some over-expressed antigens such as MUC1, PSMA, ROBO1, mesothelin, and HER2.